Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06414031

Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery

The goal of this clinical trial is to learn if the administration of tranexamic acid can reduce the necessity of blood transfusions in adult patients undergoing major abdominal surgery. . It will also inform about safety of tranexamic acid in this setting.

The main question it aims to answer is: Does tranexamic acid lower the probability of receiving at least one blood transfusion during or after surgery?

Participants will compare tranexamic acid o a placebo (a look-alike substance that contains no drug) to see if tranexamic acid works to reduce the necessity of a blood transfusion.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

University Hospital Carl Gustav Carus Dresden, Dresden, Saxony, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or above
  • Planned elective esophagectomy, gastrectomy, colectomy, rectal resection, pancreatic resection, or hepatectomy
  • Adequate renal function with serum creatinine <250 µmol/L (2.82 mg/dL)
  • Written informed consent obtained before randomization
  • Negative pregnancy test for women of childbearing potential within 14 days of commencing study treatment. Females of reproductive potential must agree to practice highly effective contraceptive measures during the study. These comprise measures with a failure rate of <1% per year when used consistently and correctly, such as intravaginal and transdermal combined (oestrogen and progestogen containing) hormonal contraception, injectable and implantable progestogen-only hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion; vasectomised partner, sexual abstinence (defined as refraining from heterosexual intercourse during the entire study period).

Exclusion criteria

  • Severe anaemia, defined as a haemoglobin concentration <8 g/dL (<5 mmol/L) or anaemia with haemoglobin concentration ≥8 to <10 g/dL (≥5,0 to <6,2 mmol/l) and one or several of the following symptoms suggesting hypoxemia:
  • Clinical signs of tachycardia, e.g., resting heart rate >100 beats/minute, palpitation etc.
  • Clinical signs of hypotension, e.g., resting systolic blood pressure <100 mmHg, orthostatic dysregulation etc.
  • Clinical signs of dyspnea, e.g., speech dyspnea, resting respiratory rate >20 breaths/min.
  • Thrombocytopenia with platelets <60 x 109 /L
  • Confirmed bleeding disorder with the need for specific preventive perioperative treatment (e.g., factor deficiency with the need of perioperative substitution)
  • A priori refusal of blood transfusions
  • Confirmed thrombophilia with a pertinent need for perioperative anticoagulation
  • Allergy / hypersensitivity to tranexamic acid
  • Recent (<30 days) thromboembolic event
  • History of medically confirmed convulsions
  • In female subjects: pregnancy or lactation

Treatment and study plan

Tranexamic Acid

Drug

Intravenous administration

Other names: Tranexamsäure Carinopharm 100mg/ml

Placebo

Drug

Intravenous administration

Other names: Isotone Kochsalz-Lösung 0,9% Infusionslösung

Primary outcomes

  1. Transfusion necessity

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

    Intra- or postoperative transfusion of at least one unit of packed red blood cells

Secondary outcomes

  1. Transfusion amount

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

    Number of transfused units of packed red blood cells per patient

  2. Blood loss

    Time frame: From skin incision to suture

    Estimated intraoperative blood loss

  3. Postoperative complications and mortality

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

    Postoperative complications and mortality assessed according to the Clavien-Dindo scheme

  4. Length of hospital stay

    Time frame: From hospital admission to discharge

    Time period from hospital admission to discharge

  5. Operation time

    Time frame: From skin incision to suture

    Time period from skin incision to suture

  6. Anesthesia time

    Time frame: From anesthesia induction to end of anesthesia

    Time period from anesthesia induction to end of anesthesia

  7. D-dimer levels

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

    Serum levels of D-dimers

  8. Adverse events

    Time frame: Until hospital discharge or 30 days postoperatively, whatever occurs earlier

    Any adverse event attributed to the intervention comprising anaphylaxis, thromboembolic events, acute renal failure, acute heart failure, seizures

Study contacts

Contact information is provided by the study sponsor or research team.

Ulrich Ronellenfitsch, MD

CONTACT

[email protected]

+493455572327

Sponsors and collaborators

Lead sponsor

Ulrich Ronellenfitsch, MD

Other

Collaborators

  • Coordinating Centre for Clinical Trials Halle
  • German Federal Ministry of Education and Research

Registry information

Official study title

Tranexamic Acid for Reduction of Intra- and Postoperative Transfusion Requirements in Elective Abdominal Surgery: Randomized Controlled Trial

Acronym: TATRA

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
May 14, 2024
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.